AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014
Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).